a Department of Psychiatry & Behavioral Sciences , Johns Hopkins University School of Medicine , Baltimore , MD , USA.
Int Rev Psychiatry. 2018 Aug;30(4):291-316. doi: 10.1080/09540261.2018.1486289. Epub 2018 Nov 13.
Humans have used serotonergic hallucinogens (i.e. psychedelics) for spiritual, ceremonial, and recreational purposes for thousands of years, but their administration as part of a structured therapeutic intervention is still a relatively novel practice within Western medical and psychological frameworks. In the mid-20 century, considerable advances were made in developing therapeutic approaches integrating administration of low () and high () doses of serotonergic hallucinogens for treatment of a variety of conditions, often incorporating psychoanalytic concepts prevalent at that time. This work contributed seminal insights regarding how these substances may be employed with efficacy and safety in targeted therapeutic interventions, including the importance of optimizing set (frame of mind) and setting (therapeutic environment). More recently, clinical and pharmacological research has revisited the effects and therapeutic potential of psychedelics utilizing a variety of approaches. The current article provides an overview of past and present models of psychedelic therapy, and discusses important considerations for future interventions incorporating the use of psychedelics in research and clinical practice.
人类数千年来一直将血清素能致幻剂(即迷幻剂)用于精神、仪式和娱乐目的,但在西方医学和心理学框架内,将其作为一种结构化治疗干预的一部分进行管理仍然是一种相对较新的做法。在 20 世纪中期,在开发整合低()和高()剂量血清素能致幻剂管理的治疗方法方面取得了相当大的进展,这些方法通常结合了当时流行的精神分析概念,用于治疗各种疾病。这项工作为这些物质如何在有针对性的治疗干预中有效和安全地使用提供了重要的见解,包括优化设定(心态)和环境(治疗环境)的重要性。最近,临床和药理学研究利用各种方法重新研究了迷幻剂的作用和治疗潜力。本文概述了过去和现在的迷幻剂治疗模型,并讨论了在研究和临床实践中纳入迷幻剂使用的未来干预措施的重要考虑因素。